Crinetics Pharmaceuticals Inc (CRNX) Stock Price, Quote & News

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant,...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 450 6464

Website: www.crinetics.com

Address:

6055 Lusk Boulevard, San Diego, United States

G101SPM Jul. 11 at 6:45 PM

#SHOWTIME ^ H.C. Wainwright Kidney Virtual Conference (July 14) Scheduled to appear: $AKBA, $UNCY ^ Endocrine Society Meeting (July 14-15) Scheduled to appear: $CRNX, $VCYT

0 · Reply

BlakeCanyon50 Jul. 11 at 4:25 PM

$ARCT & $CRNX = Took a position in both today. 2,000 ARCT & 1,000 CRNX shares.

0 · Reply

Quantumup Jul. 11 at 3:03 PM

Goldman Sachs, on 7/10,🏁 $NBIX Buy-$182. $CRNX $TAK $BMY Goldman Sachs said in its initiation report:

0 · Reply

Cryvantis Jul. 10 at 3:10 PM

$CRNX WKSP: 48k-share algo sweep punched bid wall $4.24→$4.30 🚀 Top-10 trending on X. Q beat: 26% margins, $4.1M sales, profit promise. MA stack 11 Buys, RSI 64. Gap to $5.03 only 80¢ away. Float just got lighter - buckle up!

0 · Reply

RickyGlow Jul. 9 at 2:28 PM

$CRNX Somebody knows something...easy double from here before the year is over, maybe before the Summer is over!

2 · Reply

Quantumup Jul. 9 at 10:24 AM

UBS⬆️ $NBIX PT to $174 from $152, reiterated Buy and said, "Lot less polarized vs 4Q24 and 1Q25 set-up: we expect outperformance at 2Q" $CRNX $TAK UBS added, "We continue to see steady upside on the stock for remainder of 2025. For the stock to break from the recent range-bound action, we believe consistently strong uptake on Crenessity is key. Based on our incomings, we believe the stock is lot less polarized heading into the 2Q25 print, as opposed to 4Q24 (Crenessity elevated expectations) and 1Q25 (Ingrezza bear case). We are raising our PT to $174 (from $152) based on 5.25x EV/'30E sales (prior 4.5x), supported by a DCF; we increase our multiple to reflect an increasing growth narrative with early bullish indicators for Crenessity launch. Crenessity physician checks indicate 400+ new patient starts realistic in 2Q" UBS went on to say:

0 · Reply

RickyGlow Jul. 3 at 1:57 PM

$CRNX Anyone not being these three stocks right now - $CRNX $GLXY $ASPI - just doesn't like money!

0 · Reply

Quantumup Jul. 2 at 5:57 PM

Citizens reiterated $CRNX Market Outperform-$90. $NBIX $CORT $IMVT $BBIO ARGX VRDN AMGN TRML RGLS - NVS VRTX Citizens said in its note: "Crinetics ( $CRNX, MO, $90 PT) will present Phase 2 TouCAHn data for atumelnant in congenital adrenal hyperplasia (CAH) during the oral session "All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency" on Saturday, July 12. While the abstract remains embargoed, previously released data show the once-daily oral ACTH antagonist induces rapid and sustained reductions of androstenedione and 17- hydroxyprogesterone over 12 weeks, with most patients normalizing A4 within two weeks (our coverage here). Importantly, atumelnant had greater A4 reductions than Neurocrine's ( $NBIX, NC) approved drug Crenessity, which could translate to greater glucocorticoid (GC) reductions (the regulatory endpoint). $CRNX will also present two posters on reductions in adrenal volume and 11-oxygenated androgens in the Phase 2 trial. Citizens goes on to say:

2 · Reply

TaxiBiotech_ Jun. 29 at 5:01 PM

$CRNX 🧪 Lett's dive in Crinetics’ #RDInvestorDay. They presented preclinical programs and candidates either in phase 1/2 or about to submit new INDs. 👇 1️⃣ Graves’ Disease (hyperthyroidism + thyroid eye disease) New approach: block TSHR from the inside. 🔬 In animal models: ↓ T4 levels 🧫 In patient-derived cells: ↓ hyaluronic acid 👥 Affects ~3.5M people in the US 📄 IND on the way 2️⃣ ADPKD (Autosomal Dominant Polycystic Kidney Disease) CRN10329: SST3 agonist 🔬 In animal models: ↓ cystic proliferation 📊 Table Comparing to current treatments 📄 IND coming soon 3️⃣ CRN09682 – Tumors expressing SST2 🧪 In phase 1/2 💥 Kills SST2+ "tumoral" cells 🧬 Positive animal model data 🔄 Potential to expand into other SST2+ tumors 📆 Upcoming milestones: New INDs, phase 1 readouts, PDUFA date...

0 · Reply

Quantumup Jun. 27 at 7:23 PM

H.C. Wainwright reiterated $CRNX Buy-$81 and said, "One of the pillars of our investment thesis in Crinetics has been the company's ability to discover new drugs." $NBIX H.C. Wainwright went on to say:

0 · Reply

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 10, 2025, 4:28 PM EDT - 1 day ago

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 4:05 PM EDT - 11 days ago

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Jun 16, 2025, 8:00 AM EDT - 25 days ago

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Jun 10, 2025, 4:29 PM EDT - 4 weeks ago

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 23, 2025, 8:00 AM EDT - 7 weeks ago

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

May 15, 2025, 4:05 PM EDT - 2 months ago

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

May 12, 2025, 4:05 PM EDT - 2 months ago

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2025, 1:50 PM EDT - 2 months ago

Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 2 months ago

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 11, 2025, 8:00 AM EDT - 3 months ago

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 10, 2025, 5:04 PM EDT - 3 months ago

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2025, 2:15 PM EDT - 3 months ago

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

Mar 27, 2025, 4:05 PM EDT - 3 months ago

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Mar 10, 2025, 4:36 PM EDT - 4 months ago

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 28, 2025, 1:01 PM EST - 4 months ago

Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 4 months ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:30 AM EST - 4 months ago

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Feb 20, 2025, 4:05 PM EST - 5 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Feb 10, 2025, 4:44 PM EST - 5 months ago

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2025, 4:35 PM EST - 5 months ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Jan 10, 2025, 5:15 PM EST - 6 months ago

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 10, 2025, 7:00 AM EST - 6 months ago

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan 6, 2025, 8:00 AM EST - 6 months ago

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 5:53 AM EST - 6 months ago

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Dec 10, 2024, 8:44 PM EST - 7 months ago

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 9, 2024, 8:00 AM EST - 7 months ago

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Nov 14, 2024, 4:05 PM EST - 8 months ago

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Nov 12, 2024, 11:00 PM EST - 8 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:07 PM EST - 8 months ago

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Nov 12, 2024, 4:05 PM EST - 8 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 4:05 PM EST - 8 months ago

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2024, 4:40 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 8, 2024, 11:55 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Oct 8, 2024, 4:01 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 26, 2024, 4:05 PM EDT - 10 months ago

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Sep 10, 2024, 4:40 PM EDT - 10 months ago

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 29, 2024, 4:05 PM EDT - 11 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT - 11 months ago

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 8, 2024, 9:23 PM EDT - 1 year ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 10, 2024, 7:29 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 18, 2024, 4:30 PM EDT - 1 year ago

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

Jun 10, 2024, 6:35 PM EDT - 1 year ago

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2024, 12:00 PM EDT - 1 year ago

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Jun 3, 2024, 12:00 PM EDT - 1 year ago

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)

May 30, 2024, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.

May 23, 2024, 5:45 AM EDT - 1 year ago

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 22, 2024, 8:00 AM EDT - 1 year ago

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

G101SPM Jul. 11 at 6:45 PM

#SHOWTIME ^ H.C. Wainwright Kidney Virtual Conference (July 14) Scheduled to appear: $AKBA, $UNCY ^ Endocrine Society Meeting (July 14-15) Scheduled to appear: $CRNX, $VCYT

0 · Reply

BlakeCanyon50 Jul. 11 at 4:25 PM

$ARCT & $CRNX = Took a position in both today. 2,000 ARCT & 1,000 CRNX shares.

0 · Reply

Quantumup Jul. 11 at 3:03 PM

Goldman Sachs, on 7/10,🏁 $NBIX Buy-$182. $CRNX $TAK $BMY Goldman Sachs said in its initiation report:

0 · Reply

Cryvantis Jul. 10 at 3:10 PM

0 · Reply

RickyGlow Jul. 9 at 2:28 PM

$CRNX Somebody knows something...easy double from here before the year is over, maybe before the Summer is over!

2 · Reply

Quantumup Jul. 9 at 10:24 AM

0 · Reply

RickyGlow Jul. 3 at 1:57 PM

$CRNX Anyone not being these three stocks right now - $CRNX $GLXY $ASPI - just doesn't like money!

0 · Reply

Quantumup Jul. 2 at 5:57 PM

2 · Reply

TaxiBiotech_ Jun. 29 at 5:01 PM

0 · Reply

Quantumup Jun. 27 at 7:23 PM

0 · Reply

JarvisFlow Jun. 27 at 11:30 AM

HC Wainwright & Co. has updated their rating for Crinetics Pharmaceuticals ( $CRNX ) to Buy with a price target of 81.

0 · Reply

theoptionsplug Jun. 26 at 2:44 AM

Events to Watch Tomorrow 👀 - Genpact $G is hosting an Investor Day, where it will highlight its AI-powered transformation strategy, data- and domain-centric solutions, and long-term growth plans 🤖 - It will be another active day of Fedspeak, with Richmond Federal Reserve Bank President Thomas Barkin, Federal Reserve Board Governor Michael Barr (1:15PM) and Cleveland Federal Reserve Bank President Beth Hammack (9AM) all scheduled to give talks 🎙️ - 9:00AM: Crinetics Pharmaceuticals $CRNX will host an in-person and virtual R&D Day in New York. The event will provide an update including data on the company's early-stage pipeline assets, next steps, and portfolio strategy to drive long-term value 🔬

0 · Reply

forprofit12 Jun. 25 at 3:34 PM

$CRNX added

0 · Reply

justiceforb_85 Jun. 25 at 4:52 AM

$CRNX undervalued.

1 · Reply

ribockski Jun. 15 at 6:11 AM

$CNSP $CTKB $CRNX $NVDA

0 · Reply

ribockski Jun. 9 at 3:38 AM

$CNSP 🧬 1. Cytek Biosciences (NASDAQ: $CTKB) Insider Buying: On June 2, CTKB’s CFO acquired 35,000 shares at $2.78, boosting personal holdings by ~169%—a strong internal signal. Volume Spike: Trading volume surged past 1.1M, exceeding its average of 762K—indicating heightened interest. Agent Confidence: Weighted swarm score → 89% 🧪 2. Crinetics Pharmaceuticals (NASDAQ: $CRNX) FDA Milestone: Its NDA for paltusotine has been accepted; PDUFA set for September 25, boosting innovation-driven optimism. Momentum: Price is up ~2% intraday today with increasing volume pre-market. Agent Confidence: Weighted swarm score → 86% reddit.com 🚀 3. NVIDIA (NASDAQ: $NVDA) Earnings Strength: Latest results beat expectations, driven by surging demand in AI and data center segments. Premarket Pop: Stock gained ~6% pre-market; now trading up ~1.2% intraday. Agent Confidence: Weighted swarm score → 82%

0 · Reply

BioTechHealthX May. 30 at 2:54 PM

$CRNX With global regulatory milestones, Crinetics Pharmaceuticals is on track to lead the future of endocrine disease treatment. https://biotechhealthx.com/biotech-news/crinetics-pharmaceuticals-crnx-could-be-the-next-biotech-breakout/

0 · Reply

Rage_Against_The_Machine May. 15 at 9:35 PM

Crinetics $CRNX gets a nod in the Cushing's disease race with Atumelnant Phase Ib/IIa trials slated for late 2025. Competitors like Corcept $CORT are ahead (relacorilant PDUFA Dec 2025), but the $1B+ market leaves room. CRNX's cash burn? Let's just say they're betting the farm on this pipeline. https://www.prnewswire.com/news-releases/cushings-disease-market-poised-for-significant-growth-across-the-7mm-during-the-study-period-20202034-with-rising-awareness-and-diagnostic-improvements--delveinsight-302456270.html

0 · Reply

RickyGlow May. 14 at 11:49 AM

$CRNX The last two buy recommendations have an average price of $75!

0 · Reply

Armonica423 May. 6 at 1:55 PM

$CRNX CYDY

0 · Reply

Quantumup Apr. 23 at 2:26 PM

Stifel reit'd $NBIX Buy-$166 $CRNX $TAK $ACAD $BIIB "Overall, our CAH survey of 20 physicians looks favorable for $NBIX: (1) doctors generally like Crenessity, (2) in just a few months this sample has written ~80 TRx, and (3) most notably, Crenessity is doing far better than we expected in CAH adults -- if this trend continues there could be significant upside to peak sales potential. On launch kinetics, the uptake curve here looks more like Voxzogo vs say Daybue/Skylcarys -- for example in pediatrics, doctors appear to be trying Crenessity in a few patients at first, with the expectation to ramp substantially over time. This makes sense as CAH is an unmet need, but also a disease that can be managed somewhat with cheap steroids. Overall though we've come away from this survey feeling more optimistic that 2025/2026 Crenessity consensus numbers are beatable. Meanwhile, the Ingrezza set-up remains nuanced -- but our sense is that investor expectations have substantially re-set heading into 1Q25."

0 · Reply

TheBiotechInvestor_ Apr. 21 at 9:00 PM

My next 2 investments are probably going to be $CRNX and $CYTK. Doing a deep dive this week 👌🏻

1 · Reply

Market Cap	3.03B
Revenue (ttm)	1.04M
Net Income (ttm)	-298.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28,693.27%
Debt to Equity Ratio	0.00

Volume	598,200
Avg Vol	796,718
Day's Range	N/A - N/A
Shares Out	93.63M
Stochastic %K	88%
Beta	0.25
Analysts	Strong Sell
Price Target	$73.86